Topics

CD40 Ligand Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

06:54 EST 3 Feb 2020 | BioPortfolio Reports

CD40 Ligand Pipeline Review, H2 2019


Summary


CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells.


CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG pipeline Target constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 5 and 7 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System and Genetic Disorders which include indications Autoimmune Disorders, Graft Versus Host Disease GVHD, Amyotrophic Lateral Sclerosis, Breast Cancer, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Auto Inflammatory Disease, Bladder Cancer, Colon Cancer, Hepatocellular Carcinoma, Inflammation, Kidney Transplant Rejection, Lung Adenocarcinoma, Melanoma, Metastatic Melanoma, NonSmall Cell Lung Cancer, Pancreatic Islet Transplant Rejection, Sicca Syndrome Sjogren, Solid Tumor and Transplant Rejection.


The latest report CD40 Ligand Pipeline Review, H2 2019, outlays comprehensive information on the CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Scope


The report provides a snapshot of the global therapeutic landscape for CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG

The report reviews CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG targeted therapeutics and enlists all their major and minor projects

The report assesses CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: CD40 Ligand Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

NEXT ARTICLE

More From BioPortfolio on "CD40 Ligand Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975"

Quick Search

Relevant Topics

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...